title: [Phase II clinical study of topotecan hydrochloride in patients with recurrent advanced ovarian cancer].
abstract: OBJECTIVE
  Clinical studies showed there was no satisfying treatment of the patients with recurrent advanced ovarian cancer by using chemotherapy of combining platinum, and it is very important for oncologist to seek the second-line drugs to treat the patients with recurrent ovarian cancer. The current study was designed to evaluate the efficacy and toxicity of single agent Topotecan hydrochloride in the patients with recurrent advanced ovarian cancer.
  
  
  METHODS
  A total of 31 patients with recurrent ovarian cancer in a multiple centers clinical trial were treated with Topotecan 1.25 mg/m2 qd, i.v. inf. for 5 consecutive days every three weeks.
  
  
  RESULTS
  Among 21 evaluable cases, overall response rate was 33.33%. Among 29 ITT population the response rate was 24.14%, including 3 CR and 4 PR. Main side effects were hematologic toxicities, 31.0% patients and 37.5% courses developed Grade III-IV leukocytopenia, 20.7% patients and 14.3% courses developed Grade III-IV thrombocytopemia. Non-hematologic toxicities were mild.
  
  
  CONCLUSIONS
  Topotecan is effective for treating the patients with recurrent ovarian cancer who failed with platinum-based regimes.
authors.affiliation: Cancer Center, Sun Yat-sen University, Guangzhou 510060, P. R. China.
authors.forename: Jun-dong
authors.initials: JD
authors.lastname: Li
authors.forename: Zhong-zhen
authors.initials: ZZ
authors.lastname: Guan
authors.forename: Ji-hong
authors.initials: JH
authors.lastname: Liu
authors.forename: Xiao-yan
authors.initials: XY
authors.lastname: Xin
authors.forename: Yi
authors.initials: Y
authors.lastname: Cui
authors.forename: Chang-jiang
authors.initials: CJ
authors.lastname: Huang
authors.forename: Fu-yuan
authors.initials: FY
authors.lastname: Liu
authors.forename: Lei
authors.initials: L
authors.lastname: Song
authors.forename: Mei-lu
authors.initials: ML
authors.lastname: Bian
authors.forename: Qing-hua
authors.initials: QH
authors.lastname: Zhou
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012008:Recurrence; D019772:Topotecan / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D019772:Topotecan